Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions. Here are the key drivers behind the stock’s performance:
Positive Sentiment:
Wall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
Positive Sentiment:
JPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.
Eli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth
Positive Sentiment:
Guggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.
Guggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price
Positive Sentiment:
Surging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Positive Sentiment:
The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.
Eli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s
Positive Sentiment:
Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.
Eli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings
Neutral Sentiment:
Seven analysts offered a mixed expert outlook, with ratings ranging from Hold to Buy but no consensus shift.
A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts
Neutral Sentiment:
Eli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.
The Big 3: AVGO, LLY, UBER
Neutral Sentiment:
“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.
Famous Hoosiers program to focus on Eli Lilly
Neutral Sentiment:
LLY released multiple Phase 3 pipeline updates—from Remternetug drug delivery to EMBER-3 in breast cancer and several immunology and neurological studies—underscoring broad R&D activity.
Eli Lilly’s Remternetug Study: A Step Forward in Drug Delivery
Negative Sentiment:
Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.
FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald
Negative Sentiment:
Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.
Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened
Negative Sentiment:
Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Posted 1+ days ago
AI Generated. May Contain Errors.